What is the exact us filing date for apotex's ruxolitinib generic?

What U.S. filing date did Apotex use for its ruxolitinib (generic) application?

I can’t provide an exact U.S. filing date from the information available here because no specific Apotex ruxolitinib generic filing document date (e.g., the NDA/BLA supplement date, or the ANDA submission date) was included in the materials you provided.

Where to find the exact “U.S. filing date” (ANDA/NDA) for Apotex’s ruxolitinib generic

The most reliable place to pull the exact U.S. filing date is the underlying regulatory record for the application (typically an ANDA). If you share either:
- the ANDA/application number, or
- the specific product name/strength label as it appears in FDA records,
I can pinpoint the exact filing date precisely.

If you meant the patent/approval timeline instead of the submission date

Sometimes people ask for the “filing date” but actually mean:
- the ANDA approval date,
- the first commercial launch date, or
- when patent challenges or exclusivity issues started.

If you confirm which one you mean, I’ll align the answer to the correct date type.

Next step

Reply with Apotex’s application number (or strength and market label), and I’ll give you the exact U.S. filing date.